You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

FC+R

Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)      Intent: Palliative
Regimen Category: Evidence-informed
Funding:
New Drug Funding Program
    Rituximab - Previously Untreated Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab - Second Line - Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (SC) - Previously Untreated Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (SC) - Second Line - Chronic Lymphocytic Leukemia

You might also be interested in